Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure

Journal of Geriatric Cardiology

Volumn 11, Issue 1, 2014, Pages 79-82

  Yin, Qiu Sheng ^a   Shi, Bing ^a   Dong, Lan ^a   Bi, Lei ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

B type natriuretic peptide; Diagnosis; Galectin 3; Heart failure; Preserved ejection fraction

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GALECTIN 3;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; MALE; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84902244318     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1671-5411.2014.01.014     Document Type: Article

References (12)

1. Hunt SA, Abraham WT, Chin MH, et a1. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53: el-e90.
2. Nakahara S, Oka N, Wang Y, et al. Characterization of the nuclear import pathways of Galectin-3. Cancer Res 2006; 66: 9995-10006. (Pubitemid 44672052)
3. van Kimmenade RR, Januzzi JL Jr., Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, Galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48: 1217-1224. (Pubitemid 44345127)
4. Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin ResCardiol 2010; 99: 323-328.
5. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008; 58: 88-111.
6. Ueland T, Aukrust P, Broch K, et al. Galectin-3 in heart failure: high levels are associated with all cause mortality. Int J Cardiol 2011; 150: 361-364.
7. van der Velde AR, Gullestad L, Ueland T, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure data from CORONA and COACH. Circ Heart Fail 2013; 6: 219-226.
8. Milting H, Ellinghaus P, Seewald M, et al. Plasma biomarkers of mycordial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 2008; 27: 589-596. (Pubitemid 351715387)
9. Grandin EW, Jarolim P, Murphy SA, et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem 2012; 58: 267-273.
10. de Boer RA, Verweij N, van Veldhuisen DJ, et al. A genome-wide association study of circulating galectin-3. PLoS ONE 2012; 7: e47385.
11. Chen K, Jiang RJ, Wang CQ, et al. Predictive value of plasma galectin-3 in patients with chronic heart failure. Eur Rev Med Pharmacol Sci 2013; 17: 1005-1011.
12. Lok DJ, Klip IT, Lok SI, et al. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. Am J Cardiol 2013; 112: 831-837.